

REVOLUTIONARY NEW SKIN BRIGHTENING CREAM FORMULATION USING HIGHLY SELECTIVE GROWTH FACTORS

SKINUKA bile bil * Safe and effective **non-hydroquinone** (**HQ**) **topical skin brightener** shown to improve hyperpigmentation.

* Growth factor-based technology similar to Skinuva® Scar.

* Key ingredients include selective **synthetic Growth Factors**, **Tranexamic Acid**, **Vitamin C**, **Niacinamide**, and **Arbutin**.

* Found to be nearly **30% more effective** in improving hyperpigmentation when compared to HQ in a head-to-head split study.

* No HQ, retinol, or silicone, dermatologist tested, and safe for **long term, daily use and for pregnant and breastfeeding** women!

WE TREAT HYPERPIGMENTATION BETTER THAN THEM, AND HERE'S WHY

Consumer demand for safe and effective non-hydroquinone (HQ) topical products

There has been a lack of safe and effective non-HQ products for treating hyperpigmentation. Skinuva® Brite is a non-HQ Growth Factor-based product along with Tranexamic Acid and other ingredients, that has been shown to be *nearly 30% more effective in improving hyperpigmentation than HQ4% in our most recent head-to-head clinical trial.*

Skinuva® Brite was also shown to be tolerated very well with minimal irritation and redness.

Patience in research and formulation were keys to success for Skinuva® Brite

Using published medical literature and clinical data, Skinuva's team of physicians and scientists were able to integrate clinically proven ingredients to create what is now regarded as one of the most advanced topical creams for hyperpigmentation.

Skinuva® Brite should be used twice a day, morning and night, on areas of hyperpigmentation and sunscreen may be worn over it.





MD Medical Designs, Inc. 113 N San Vicente Blvd, Suite #6 Beverly Hills, CA 90211 P: 310-873-3912 Email: orders@skinuva.com

* Safe for long term daily use for hyperpigmentation including melasma, post-inflammatory hyperpigmentation, under eye hyperpigmentation, and sun spots.

- * Results may be seen as early as 30 days, but for best results, long term use is recommended.
- * Results may vary depending on severity of hyperpigmentation.

Our clinical results speak for themselves...

Clinical trial facts

Photographs were taken using high resolution 3D imaging Canfield Vectra system.

Our split study included 18 patients, one side of their face with hyperpigmentation was treated with Skinuva® Brite twice daily, and the other half with HQ4% nightly for one month. Patient reported outcomes were used for assessment, and 5 independent physician evaluators graded the images.

Clinical Results

- 1. Patients reported Skinuva® Brite to be **29% more effective than HQ4%**, and similarly, the independent evaluators reported Skinuva® Brite to be **27% more effective than HQ4%**.
- 2. In **over 83% of cases**, both patients and independent evaluators reported that the side treated with Skinuva® Brite had a **better overall appearance** than HQ4%.
- 3. **0%** of patents reported irritation and tolerability issues with Skinuva® Brite, while 27.8% of patients reported irritation with HQ4%, p<0.05



Before (left) and after (right) 4 weeks of once daily application of **HQ4**% for cheek melasma. Moderate redness and mild irritation was noted after one month of use.

Before (left) and after (right) 4 weeks of twice daily application of **Skinuva™ Brite** for cheek melasma. Moderate improvement is noted with Skinuva™ Brite.

